[Federal Register Volume 66, Number 16 (Wednesday, January 24, 2001)]
[Notices]
[Pages 7653-7654]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-2109]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Advisory Committee on Immunization Practices: Meeting

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (P.L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following committee meeting:

    Name: Advisory Committee on Immunization Practices (ACIP).
    Times and Dates: 8:30 a.m.-6:45 p.m., February 21, 2001; 8 a.m.-
3:15 p.m., February 22, 2001.
    Place: Atlanta Marriott Century Center, 2000 Century Boulevard, 
N.E., Atlanta, Georgia 30345-3377.
    Status: Open to the public, limited only by the space available.
    Purpose: The Committee is charged with advising the Director, 
CDC, on the appropriate uses of immunizing agents. In addition, 
under 42 U.S.C. 1396s, the Committee is mandated to establish and 
periodically review and, as appropriate, revise the list of vaccines 
for administration to vaccine-eligible children through the Vaccines 
for Children (VFC) program, along with schedules regarding the 
appropriate periodicity, dosage, and contraindications applicable to 
the vaccines.
    Matters to be Discussed: The agenda will include a discussion on 
the U.S. influenza surveillance summary; international update and 
vaccine selection for 2001-2002 influenza season; 2001-2002 control 
and prevention of influenza recommendations; update on live 
attenuated influenza vaccine; status report of ACIP statement on 
prevention of hepatitis B; update on thimerosal and DTaP vaccines; 
options to transition to thimerosal free DTaP vaccines; polio 
outbreak in the Dominican Republic; status of outbreak and control 
measures; policy implications for polio vaccine in the U.S.; stock 
pile of polio vaccine; update from the Haemophilus influenza b 
vaccine dose-reduction working group; smallpox vaccine 
recommendations; recommended use of vaccine for laboratorians 
working with highly-attenuated and non-attenuated strains of 
vaccinia virus or other or thopoxviruses; recommended use of vaccine 
in a bioterrorism event involving smallpox virus; recommendations 
regarding antiviral alternatives to VIG for treating vaccine adverse 
reactions; update from the National Center for Infectious Diseases; 
update from the National Immunization Program; update

[[Page 7654]]

from the Food and Drug Administration; update from the National 
Institutes of Health; update from the Vaccine Injury Compensation 
Program; update from the National Vaccine Program; Institute of 
Medicine report on the Immunization Safety Review Committee; review 
and approval of the general recommendations document; 
discontinuation of manufacture and marketing of the only licensed 
cholera vaccine in the U.S. and the only licensed typhoid fever 
vaccine for children age 6 months-2 years in the U.S.; pertussis 
among adolescents and adults in the U.S.; data from the APERT trial; 
update on Td vaccine supply; update on hepatitis A vaccination 
activities; cost effectiveness of universal childhood vaccination 
against hepatitis A in states covered by ACIP recommendations; and a 
StaphVAX phase 3 efficacy trial in end-stage renal disease patients 
on hemodialysis.
    Agenda items are subject to change as priorities dictate.
    Contact Person for More Information: Gloria A. Kovach, Program 
Analyst, Epidemiology and Surveillance Division, National 
Immunization Program, CDC,1600 Clifton Road, NE., m/s E61, Atlanta, 
Georgia 30333. Telephone 404/639-8096.
    The Director, Management Analysis and Services office has been 
delegated the authority to sign Federal Register notices pertaining 
to announcements of meetings and other committee management 
activities for both the Centers for Disease Control and Prevention 
and the Agency for Toxic Substances and Disease Registry.

    Dated: January 18, 2001.
Carolyn J. Russell,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 01-2109 Filed 1-23-01; 8:45 am]
BILLING CODE 4163-18-P